Clear Harbor Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Clear Harbor Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,400	Closed	-$443K	–	420
2023 Q1	$443K	Hold	18,400	–	–	0.05%	253
2022 Q4	$194K	Buy	18,400 +900	+5%	+$7.26K	0.02%	320
2022 Q3	$79K	Buy	17,500 +800	+5%	+$3.65K	0.01%	346
2022 Q2	$67K	Hold	16,700	–	–	0.01%	377
2022 Q1	$122K	Hold	16,700	–	–	0.01%	373
2021 Q4	$94K	Sell	16,700 -1,100	-6%	-$6.99K	0.01%	389
2021 Q3	$114K	Hold	17,800	–	–	﹤0.01%	361
2021 Q2	$150K	Buy	17,800 +900	+5%	+$7.26K	0.02%	338
2021 Q1	$177K	Buy	16,900 +600	+4%	+$8.44K	0.02%	307
2020 Q4	$276K	Buy	16,300 +300	+2%	+$4.5K	0.04%	234
2020 Q3	$205K	Hold	16,000	–	–	0.04%	244
2020 Q2	$226K	Buy	16,000 +500	+3%	+$6.31K	0.04%	226
2020 Q1	$143K	Hold	15,500	–	–	0.03%	236
2019 Q4	$231K	Hold	15,500	–	–	0.04%	245
2019 Q3	$106K	Buy	+15,500	New	+$157K	0.02%	243

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Clear Harbor Asset Management's PRVB Position: Q2 2023 in Review

Clear Harbor Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 18,400 shares — an estimated $443K sold.

Clear Harbor Asset Management first reported a position in PRVB in Q3 2019 and held it in 15 quarters. The position peaked at $443K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Clear Harbor Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Clear Harbor Asset Management sold 18,400 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $443K.
Clear Harbor Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
Clear Harbor Asset Management's Provention Bio, Inc. Common Stock position peaked at $443K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Clear Harbor Asset Management's 13F filing for Q2 2023, filed 21 Jul 2023.